Long-lasting benefit on multimodal treatment combining osimertinib and stereotaxic radiotherapy for metastatic non-small cell lung cancer with the EGFR exon 20 insertion 773-774 HVdelinsLM: a case report

Erlotinib Response in a Non-Small Cell Lung Cancer Patient with EGFR Exon 20 Mutation

Long-Term Treatment with Erlotinib for EGFR Wild-Type Non-Small Cell Lung Cancer: A Case Report

The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are known to have greater efficacy in EGFR mutation-positive non-small cell lung cancer (NSCLC), although erlotinib also has activity in wild-type disease. We report the successful long-term maintenance treatment of a patient with EGFR wild-type NSCLC with gefitinib and later erlotinib. The pat...

Advanced EGFR mutation-positive non-small-cell lung cancer: case report, literature review, and treatment recommendations.

BACKGROUND Lung cancer is the leading cause of cancer mortality. Non-small-cell lung cancer (NSCLC) comprises up to 90% of all lung cancers. Conventional treatment for advanced NSCLC consists of chemotherapy and has a small impact on survival. Molecular targets, such as epidermal growth factor receptor (EGFR), involved in cell signaling have led to the development of new, targeted therapies ove...

Role of Radiotherapy in Metastatic Non-Small Cell Lung Cancer

Radiotherapy has had important role in the palliation of NSCLC. Randomized trials tend to suggest that, in general, short regimens give similar palliation and toxicity compared to longer regimens. The benefit of combining chemotherapy to radiosensitize the palliative radiation treatment is an open question, but so far it has not been proved to be very useful in NSCLC. The addition of molecular ...

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer

Osimertinib has been demonstrated to overcome the epidermal growth factor receptor (EGFR)-T790M, the most relevant acquired resistance to first-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs). However, the C797S mutation, which impairs the covalent binding between the cysteine residue at position 797 of EGFR and osimertinib, induces resistance to osimertinib. Currently, there are no effe...